ClinicalTrials.gg
CompletedNCT02554773Updated Jun 5, 2024Results posted

An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B

A Phase 1/2 interventional study of Fitusiran (SAR439774) in Hemophilia A and Hemophilia B, sponsored by Genzyme, a Sanofi Company. Completed at 12 sites in 5 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-05.

Sponsored by Genzyme, a Sanofi Company (part of Sanofi) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
34
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing fitusiran in Hemophilia A — 2 open to participants now, 3 under way, 2 of them phase 3. fitusiran · Hemophilia A.

Enrollment
8th of 10
34 · median 70
Started
2015
the only one that year
Phase 1/2
Only one
of the 10
Registered
2nd of 10
by date
Lead sponsor
6 of 10
Genzyme, a Sanofi Company

Among the 10 studies testing fitusiran in Hemophilia A, this one is the 8th largest by enrollment, is the only one that started in 2015, is the only one in phase 1/2, and was the 2nd registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

2 of the 10 studies testing fitusiran in Hemophilia A are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fitusiran

fitusiran: first FDA approval 2025 (QFITLIA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing fitusiran in Hemophilia A, or all of them as a file.
02

Study summary

Primary Objective:

To evaluate the long-term safety and tolerability of fitusiran in male patients with moderate or severe hemophilia A or B

Secondary Objectives:

  • To investigate the long-term efficacy of fitusiran
  • To characterize the safety and efficacy of concomitantly administered Factor VIII (FVIII), Factor IX (FIX) or bypassing agents (BPA) and fitusiran for treatment of bleeding episodes
  • To assess changes in health-related quality of life (QOL) over time
  • To characterize antithrombin (AT) reduction and thrombin generation (TG) increase
  • To characterize the pharmacokinetics (PK) of fitusiran
Read the detailed description

It is anticipated that patients in this study will receive treatment with open label fitusiran for approximately 7 years or until fitusiran becomes commercially available, whichever occurs first.

03

Conditions studied

  • Hemophilia A
  • Hemophilia B

Keywords

  • Hemophilia
  • RNAi therapeutic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completed and tolerated study drug dosing in study TDR14767 (ALN-AT3SC-001)
  • Male aged ≥18 years
  • Moderate or severe, clinically stable hemophilia A or B as evidenced by a laboratory FVIII or FIX level ≤5% at screening. Patients with a FVIII or FIX level >5% at screening will be eligible on provision of a historic laboratory report indicating a trough level ≤5%
  • Willing and able to comply with the study requirements and provide written

Exclusion criteria

Exclusion Criteria:

  • liver disease
  • Patients known to be seropositive and have a \<200 cells/μL
  • History of venous thromboembolism
  • Current serious mental illness that, in the judgment of the Investigator, may compromise patient safety, ability to participate in all study assessments, or study integrity
  • Clinically relevant history or presence of cardiovascular, respiratory, gastrointestinal, renal, neurological, inflammatory, or other diseases that, in the judgment of the Investigator, precludes study participation
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Fitusiran

    Patients will be administered subcutaneous (SC) fitusiran once monthly or every 2 months according to the dose selection rules defined in protocol.

    Drug: Fitusiran (SAR439774)

Interventions

  • Pharmaceutical form: solution for injection Route of administration : subcutaneous (sc)

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs)

    An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An SAE is any untoward medical occurrence that results: death or life-threatening or inpatient hospitalization or prolongation of existing hospitalization or persistent or significant disability or congenital anomaly or medically important event. All AEs collected in LTE14762 were considered TEAE because all participants received dose in the parent study. AEs of special interest (AESI) are alanine aminotransferase (ALT) or aspartate aminotransferase (AST) elevations \>3× upper limit of normal (ULN) or suspected or confirmed thromboembolic events or severe or serious injection site reactions or systemic injection associated reactions or cholecystitis or cholelithiasis.

    Time frame: From first dose of study drug (Day 1) up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)

  2. Number of Participants With Potentially Clinically Significant Abnormality (PCSA): Hematology

    Blood samples were collected to determine the hematology laboratory significant abnormalities. Here, DFB = decrease from baseline, NB = non-black, and B = black.

    Time frame: From first dose of study drug (Day 1) up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)

  3. Number of Participants With Potentially Clinically Significant Abnormality: Clinical Chemistry

    Blood samples were collected to determine the clinical chemistry laboratory abnormalities. Here, mmol/L = millimoles per liter, LLN = lower limit of normal, mg/L = milligram per liter, umol/L = micromoles per liter, mL/min = milliliter per minute, m\^2 = meter square, CB = conjugated bilirubin, and DB = direct bilirubin.

    Time frame: From first dose of study drug (Day 1) up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)

  4. Number of Participants With Potentially Clinically Significant Abnormality: Urinalysis

    Urine samples collected to determine the significant abnormalities in urine.

    Time frame: From first dose of study drug (Day 1) up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)

  5. Number of Participants With Potentially Clinically Significant Abnormality: Vital Signs

    Participants vital signs were examined to determine the abnormalities. Vital signs included weight, supine systolic blood pressure (SSBP) and supine diastolic blood pressure (SDBP). Here, mmHg = millimeter of mercury, and IFB = increase from baseline.

    Time frame: From first dose of study drug (Day 1) up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)

  6. Number of Participants With Potentially Clinically Significant Abnormality: Electrocardiogram (ECG)

    Standard 12-lead ECGs were recorded after at least 15 minutes in the supine position using an electrocardiographic device. The following were assessed: heart rate, rhythm, interval between the peaks of successive QRS complexes (RR), interval from the beginning of the P wave until the beginning of the QRS complex (PR), interval from start of the Q wave to the end of the S wave (QRS), interval between the start of the Q wave and the end of the T wave (QT), QT interval corrected for heart rate (QTc) automatic correction evaluation, QRS axis, left ventricular hypertrophy criteria, right ventricular hypertrophy criteria, repolarization charges, and overall cardiac impression for each participant. Here, msec = milliseconds.

    Time frame: From first dose of study drug (Day 1) up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)

  7. Number of Participants With Potentially Clinically Significant Abnormality: Physical Examination

    Physical examination included, at a minimum, an assessment of the participant's general appearance; skin; head, eyes, ears, nose, and throat; examinations of lymph nodes, abdomen, extremities/joints, neurological and mental status; heart and respiratory auscultation; peripheral arterial pulse; and pupil, knee, achilles, and plantar reflexes.

    Time frame: From first dose of study drug (Day 1) up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)

Secondary outcomes

  1. Annualized Bleeding Rate (ABR) During the Efficacy Period

    The ABR was annualized for each participant using the following formula: ABR = total number of bleeding events/total number of days in the respective period x 365.25. The efficacy period was defined as treatment Day 29 to earlier of end of study date before the dose pause or the last fitusiran administration date before the dose pause + 28 days, whichever comes first for original dose regimen (SAS 1) and the dose re-start Day 169 to the end of study visit for AT-based dose regimen (SAS 2).

    Time frame: From Day 29 up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)

  2. Annualized Spontaneous Bleeding Rate During the Efficacy Period

    A spontaneous bleeding episode was defined as a bleeding event that occurred for no apparent or known reason, particularly into the joints, muscles, and soft tissues. The efficacy period was defined as treatment Day 29 to earlier of end of study date before the dose pause or the last fitusiran administration date before the dose pause + 28 days, whichever comes first for original dose regimen (SAS 1) and the dose re-start Day 169 to the end of study visit for AT-based dose regimen (SAS 2).

    Time frame: From Day 29 up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)

  3. Annualized Joint Bleeding Rate During the Efficacy Period

    A joint bleeding episode was defined as an event that is characterized by an unusual sensation in the joint ("aura") in combination with 1) increasing swelling or warmth over the skin over the joint; 2) increasing pain; or 3) progressive loss of range of motion or difficulty in using the limb as compared with baseline. The efficacy period was defined as treatment Day 29 to earlier of end of study date before the dose pause or the last fitusiran administration date before the dose pause + 28 days, whichever comes first for original dose regimen (SAS 1) and the dose re-start Day 169 to the end of study visit for AT-based dose regimen (SAS 2).

    Time frame: From Day 29 up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)

  4. Time Intervals Between Bleeding Events

    Bleed-free duration was defined as the time interval between 2 protocol-defined treated bleeding events, excluding events that occurred during the intercurrent periods.

    Time frame: From Day 29 up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)

  5. Annualized Weight-Adjusted Consumption of Coagulation Factor VIII (FVIII) and Coagulation Factor IX (FIX)

    Number of coagulation factor injections per bleed was determined. IU= international units, and kg= kilogram.

    Time frame: From Day 29 up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)

  6. Annualized Weight-Adjusted Consumption of Bypassing Agent (BPA) of Recombinant Factor VIIa (rFVIIa)

    Number of BPA injections per bleed was determined.

    Time frame: From Day 29 up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)

  7. Annualized Weight-Adjusted Consumption of Bypassing Agent (BPA) of Activated Prothrombin Complex Concentrate (aPCC)

    Number of BPA injections per bleed was determined.

    Time frame: From Day 29 up to end of the study, maximum of up to 76 months

  8. Change From Baseline in EuroQoL 5-Dimension 5-level Questionnaire (EQ-5D-5L) Index and Visual Analog Scale (VAS) Scores at Month 24

    The EQ-5D-5L is a standardized and disease-generic instrument for use as a measure of quality of life (QoL) outcome. The EQ-5D-5L consists of 2 parts: EQ-5D descriptive system and EQ VAS. The EQ-5D descriptive system included questions for each of following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The VAS recorded participant's self-rated health on a vertical 20-centimeter. VAS scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). The EQ-5D-5L questionnaire scores range from 0-100, where 0= worst self-perceived health and 100= best self-perceived health. Positive change from baseline indicates an improvement in QoL. Baseline refers to the last non-missing value on or before the first significant treatment in TDR14767(ALN-AT3SC-001) or LTE14762 study.

    Time frame: Baseline and Month 24

  9. Change From Baseline in Hemophilia Quality of Life Questionnaire (Haem-A-QoL) Total Score and Physical Health Scores at Month 24

    The Haem-A-QoL questionnaire is psychometrically tested QoL assessment instrument for participants with hemophilia and includes 46 items contributing to 10 QoL domains (physical health, feelings, view of yourself, sports and leisure, work and school, dealing with hemophilia, treatment, future, family planning, partnership and sexuality). Scoring for each item is based on a 5-point Likert scale (1= never, 2= rarely, 3= sometimes, 4= often, and 5= all the time), and the physical health and total transformed scores range from 0 to 100. Higher scores indicated greater impairment. Baseline refers to the last non-missing value on or before the first significant treatment in TDR14767(ALN-AT3SC-001) or LTE14762 study.

    Time frame: Baseline and Month 24

  10. Antithrombin Activity Level at the End of Treatment Regimen

    The AT activity level was analyzed up to end of treatment regimen. The baseline under the original dose and regimen was the last non-missing assessment before the first significant dose.

    Time frame: From Day 29 up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)

  11. Thrombin Generation at the End of Treatment Regimen

    The TG data was analyzed by CoagScope and assay performed using calibrated automated thrombogram method. The baseline under the original dose and regimen was the last non-missing assessment before the first significant dose.

    Time frame: From Day 29 up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)

  12. Maximum Observed Concentration (Cmax) of Fitusiran

    Cmax was defined as maximum plasma concentration observed. The non-compartmental Pharmacokinetic (PK) analysis was performed.

    Time frame: Pre-dose and 0.5, 2, 4, 8 and 24 hours post-dose on Day 1, and Months 12 and 24

  13. Time to Reach the Maximum Concentration (Tmax) of Fitusiran

    tmax was defined as time to reach Cmax. The non-compartmental PK analysis was performed.

    Time frame: Pre-dose and 0.5, 2, 4, 8 and 24 hours post-dose on Day 1, and Months 12 and 24

  14. Area Under the Concentration Versus Time Curve From Time 0 to the Real Time (AUClast) of Fitusiran

    AUClast was defined as area under the concentration versus time curve from time 0 to the last measurable concentration. The non-compartmental PK analysis was performed.

    Time frame: Pre-dose and 0.5, 2, 4, 8 and 24 hours post-dose on Day 1, and Months 12 and 24

  15. Area Under the Concentration Versus Time Curve Extrapolated to Infinity (AUCinf) of Fitusiran

    AUCinf was defined as area under the concentration versus time curve extrapolated to infinity. The non-compartmental PK analysis was performed.

    Time frame: Pre-dose and 0.5, 2, 4, 8 and 24 hours post-dose on Day 1 and Month 12

  16. Terminal Half-Life (t1/2z) of Fitusiran

    t1/2z associated with the terminal slope (λz) determined according to the following equation: t1/2z = 0.693/λz; where, λz is the slope of the regression line of the terminal phase of the plasma concentration versus time curve, in semi-logarithmic scale. The non-compartmental PK analysis was performed.

    Time frame: Pre-dose and 0.5, 2, 4, 8 and 24 hours post-dose on Day 1 and Month 12

  17. Apparent Total Body Clearance (CL/F) of Fitusiran

    CL/F was defined as apparent clearance of study drug from the body. The non-compartmental PK analysis was performed.

    Time frame: Pre-dose and 0.5, 2, 4, 8 and 24 hours post-dose on Day 1 and Month 12

  18. Apparent Volume of Distribution at the Steady State After Single Extravascular Dose (Vss/F) of Fitusiran

    Vss/F was defined as apparent volume of distribution of study drug at steady state concentration. The non-compartmental PK analysis was performed.

    Time frame: Pre-dose and 0.5, 2, 4, 8 and 24 hours post-dose on Day 1 and Month 12

  19. Recovery of Fraction of the Dose Excreted in Urine (fe) in 0-24 Hours After Fitusiran Administration

    fe was defined as the amount of fitusiran excreted in urine in 0-24 hour. The non-compartmental PK analysis was performed.

    Time frame: Postdose, 0 to 6 hours, 6 to 12 hours, 12 to 24 hours at Month 24

07

Results

Posted Jun 5, 2024

Participant flow

The study was conducted at 13 centers in 5 countries between 18 September 2015 and 21 March 2023. A total of 34 participants were enrolled in this study.

Original Dose Regimen (SAS 1)
Participant flow — Original Dose Regimen (SAS 1)
MilestoneOriginal Dose Regimen [Safety Analysis Set 1 (SAS 1)]Antithrombin (AT)-Based Dose Regimen [Safety Analysis Set 2 (SAS 2)]
Started340
Completed180
Not completed160
Withdrew: Physician decision10
Withdrew: Withdrawal by subject70
Withdrew: Adverse event30
Withdrew: Death10
Withdrew: Other40
AT-Based Dose Regimen (SAS 2)
Participant flow — AT-Based Dose Regimen (SAS 2)
MilestoneOriginal Dose Regimen [Safety Analysis Set 1 (SAS 1)]Antithrombin (AT)-Based Dose Regimen [Safety Analysis Set 2 (SAS 2)]
Started018
Completed012
Not completed06
Withdrew: Withdrawal by subject01
Withdrew: More than 1 at measurement <15%01
Withdrew: Adverse event01
Withdrew: Other03

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs)

An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An SAE is any untoward medical occurrence that results: death or life-threatening or inpatient hospitalization or prolongation of existing hospitalization or persistent or significant disability or congenital anomaly or medically important event. All AEs collected in LTE14762 were considered TEAE because all participants received dose in the parent study. AEs of special interest (AESI) are alanine aminotransferase (ALT) or aspartate aminotransferase (AST) elevations \>3× upper limit of normal (ULN) or suspected or confirmed thromboembolic events or severe or serious injection site reactions or systemic injection associated reactions or cholecystitis or cholelithiasis.

Time frame:
From first dose of study drug (Day 1) up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs)
ParticipantsOriginal Dose Regimen (SAS 1)AT-Based Dose Regimen (SAS 2)
Any TEAE3314
Any Treatment-emergent SAE131
Any Treatment-emergent AESI111
Any TEAE leading to study drug discontinuation51
Any TEAE leading to death10
PrimaryNumber of Participants With Potentially Clinically Significant Abnormality (PCSA): Hematology

Blood samples were collected to determine the hematology laboratory significant abnormalities. Here, DFB = decrease from baseline, NB = non-black, and B = black.

Time frame:
From first dose of study drug (Day 1) up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Abnormality (PCSA): Hematology
ParticipantsOriginal Dose Regimen (SAS 1)AT-Based Dose Regimen (SAS 2)
Hemoglobin: <= 115 gram per liter (g/L)52
Hemoglobin: >= 185 g/L31
Hemoglobin: DFB >= 20 g/L103
Hematocrit: <= 0.37 fraction of 183
Hematocrit: >= 0.55 fraction of 152
Erythrocyte Count: >= 6 x 10^12/L93
Platelet Count: < 100 x 10^9/L20
Leukocyte Count: <3 x 10^9/L (NB); <2 x 10^9/L (B)31
Leukocyte Count: >= 16 x 10^9/L11
Neutrophils: <1.5 x 10^9/L (NB); <1 x 10^9/L (B)82
Lymphocytes: > 4 x 10^9/L01
Monocytes: > 0.7 x 10^9/L153
Basophils: > 0.1 x 10^9/L40
Eosinophils:>0.5x10^9/L or >ULN (ULN >=0.5x10^9/L)111
PrimaryNumber of Participants With Potentially Clinically Significant Abnormality: Clinical Chemistry

Blood samples were collected to determine the clinical chemistry laboratory abnormalities. Here, mmol/L = millimoles per liter, LLN = lower limit of normal, mg/L = milligram per liter, umol/L = micromoles per liter, mL/min = milliliter per minute, m\^2 = meter square, CB = conjugated bilirubin, and DB = direct bilirubin.

Time frame:
From first dose of study drug (Day 1) up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Abnormality: Clinical Chemistry
ParticipantsOriginal Dose Regimen (SAS 1)AT-Based Dose Regimen (SAS 2)
Glucose: <= 3.9 mmol/L and < LLN132
Glucose:>=11.1 mmol/L(unfasted);>=7 mmol/L(fasted)102
C-Reactive Protein: > 2 ULN or > 10 mg/L207
Sodium: <= 129 mmol/L10
Potassium: < 3 mmol/L20
Potassium: >= 5.5 mmol/L50
Creatinine: >= 150 umol/L11
Creatinine: >= 30% change from baseline137
Creatinine: >= 100% change from baseline21
Creatinine Clearance: >= 60 - < 90 mL/min/1.73m^2182
Creatinine Clearance: >= 15 - < 30 mL/min/1.73m^211
Uric Acid: < 120 umol/L20
Uric Acid: > 408 umol/L208
ALT: > 1 ULN306
ALT: > 3 ULN141
ALT: > 5 ULN61
ALT: > 10 ULN20
ALT: > 20 ULN10
AST: > 1 ULN227
AST: > 3 ULN81
AST: > 5 ULN50
AST: > 10 ULN10
Alkaline Phosphatase: > 1.5 ULN40
Total Bilirubin: > 1.5 ULN42
CB: DB >35% Bilirubin and Bilirubin >1.5 ULN31
PrimaryNumber of Participants With Potentially Clinically Significant Abnormality: Urinalysis

Urine samples collected to determine the significant abnormalities in urine.

Time frame:
From first dose of study drug (Day 1) up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Abnormality: Urinalysis
ParticipantsOriginal Dose Regimen (SAS 1)AT-Based Dose Regimen (SAS 2)
Number of Participants With Potentially Clinically Significant Abnormality: Urinalysis00
PrimaryNumber of Participants With Potentially Clinically Significant Abnormality: Vital Signs

Participants vital signs were examined to determine the abnormalities. Vital signs included weight, supine systolic blood pressure (SSBP) and supine diastolic blood pressure (SDBP). Here, mmHg = millimeter of mercury, and IFB = increase from baseline.

Time frame:
From first dose of study drug (Day 1) up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Abnormality: Vital Signs
ParticipantsOriginal Dose Regimen (SAS 1)AT-Based Dose Regimen (SAS 2)
SSBP: >= 160 mmHg; IFB >= 20 mmHg10
SDBP: <= 45 mmHg; DFB >= 20 mmHg10
Weight: >= 5% DFB83
Weight: >= 5% IFB159
PrimaryNumber of Participants With Potentially Clinically Significant Abnormality: Electrocardiogram (ECG)

Standard 12-lead ECGs were recorded after at least 15 minutes in the supine position using an electrocardiographic device. The following were assessed: heart rate, rhythm, interval between the peaks of successive QRS complexes (RR), interval from the beginning of the P wave until the beginning of the QRS complex (PR), interval from start of the Q wave to the end of the S wave (QRS), interval between the start of the Q wave and the end of the T wave (QT), QT interval corrected for heart rate (QTc) automatic correction evaluation, QRS axis, left ventricular hypertrophy criteria, right ventricular hypertrophy criteria, repolarization charges, and overall cardiac impression for each participant. Here, msec = milliseconds.

Time frame:
From first dose of study drug (Day 1) up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Abnormality: Electrocardiogram (ECG)
ParticipantsOriginal Dose Regimen (SAS 1)AT-Based Dose Regimen (SAS 2)
Ventricular Rate: < 50 beats/min10
Ventricular Rate: > 90 beats/min85
Ventricular Rate: >90 beats/min;IFB >=20 beats/min31
Ventricular Rate: > 100 beats/min51
Ventricular Rate:>100 beats/min;IFB >=20 beats/min10
PR Interval: > 200 msec30
PR Interval: > 200 msec; IFB >= 25%20
PR Interval: > 220 msec20
PR Interval: > 220 msec; IFB >= 25%20
PR Interval: > 240 msec20
PR Interval: > 240 msec;IFB >= 25%20
QRS Interval: > 110 msec83
QRS Interval: > 110 msec; IFB >= 25%30
QRS Interval: > 120 msec32
QRS Interval: > 120 msec; IFB >= 25%30
QTc Bazett: > 450 msec24
QTc Bazett: > 480 msec11
QTc Bazett: IFB (30-60) msec84
QTc Fridericia: > 450 msec11
QTc Fridericia: > 480 msec01
QTc Fridericia: IFB (30-60) msec44
PrimaryNumber of Participants With Potentially Clinically Significant Abnormality: Physical Examination

Physical examination included, at a minimum, an assessment of the participant's general appearance; skin; head, eyes, ears, nose, and throat; examinations of lymph nodes, abdomen, extremities/joints, neurological and mental status; heart and respiratory auscultation; peripheral arterial pulse; and pupil, knee, achilles, and plantar reflexes.

Time frame:
From first dose of study drug (Day 1) up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Abnormality: Physical Examination
ParticipantsOriginal Dose Regimen (SAS 1)AT-Based Dose Regimen (SAS 2)
Number of Participants With Potentially Clinically Significant Abnormality: Physical Examination172
SecondaryAnnualized Bleeding Rate (ABR) During the Efficacy Period

The ABR was annualized for each participant using the following formula: ABR = total number of bleeding events/total number of days in the respective period x 365.25. The efficacy period was defined as treatment Day 29 to earlier of end of study date before the dose pause or the last fitusiran administration date before the dose pause + 28 days, whichever comes first for original dose regimen (SAS 1) and the dose re-start Day 169 to the end of study visit for AT-based dose regimen (SAS 2).

Time frame:
From Day 29 up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
Reported as:
Mean · bleeding events per year
Annualized Bleeding Rate (ABR) During the Efficacy Period
bleeding events per yearOriginal Dose Regimen (SAS 1)AT-Based Dose Regimen (SAS 2)
Annualized Bleeding Rate (ABR) During the Efficacy Period3.035 (1.845 to 4.992)3.929 (1.622 to 9.520)
SecondaryAnnualized Spontaneous Bleeding Rate During the Efficacy Period

A spontaneous bleeding episode was defined as a bleeding event that occurred for no apparent or known reason, particularly into the joints, muscles, and soft tissues. The efficacy period was defined as treatment Day 29 to earlier of end of study date before the dose pause or the last fitusiran administration date before the dose pause + 28 days, whichever comes first for original dose regimen (SAS 1) and the dose re-start Day 169 to the end of study visit for AT-based dose regimen (SAS 2).

Time frame:
From Day 29 up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
Reported as:
Mean · bleeding events per year
Annualized Spontaneous Bleeding Rate During the Efficacy Period
bleeding events per yearOriginal Dose Regimen (SAS 1)AT-Based Dose Regimen (SAS 2)
Annualized Spontaneous Bleeding Rate During the Efficacy Period2.60 ± 5.963.96 ± 11.64
SecondaryAnnualized Joint Bleeding Rate During the Efficacy Period

A joint bleeding episode was defined as an event that is characterized by an unusual sensation in the joint ("aura") in combination with 1) increasing swelling or warmth over the skin over the joint; 2) increasing pain; or 3) progressive loss of range of motion or difficulty in using the limb as compared with baseline. The efficacy period was defined as treatment Day 29 to earlier of end of study date before the dose pause or the last fitusiran administration date before the dose pause + 28 days, whichever comes first for original dose regimen (SAS 1) and the dose re-start Day 169 to the end of study visit for AT-based dose regimen (SAS 2).

Time frame:
From Day 29 up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
Reported as:
Mean · bleeding events per year
Annualized Joint Bleeding Rate During the Efficacy Period
bleeding events per yearOriginal Dose Regimen (SAS 1)AT-Based Dose Regimen (SAS 2)
Annualized Joint Bleeding Rate During the Efficacy Period3.51 ± 6.974.78 ± 11.76
SecondaryTime Intervals Between Bleeding Events

Bleed-free duration was defined as the time interval between 2 protocol-defined treated bleeding events, excluding events that occurred during the intercurrent periods.

Time frame:
From Day 29 up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
Reported as:
Median · days
Time Intervals Between Bleeding Events
daysOriginal Dose Regimen (SAS 1)AT-Based Dose Regimen (SAS 2)
Time Intervals Between Bleeding Events368.50 (56.0 to 1576.0)249.00 (11.0 to 427.0)
SecondaryAnnualized Weight-Adjusted Consumption of Coagulation Factor VIII (FVIII) and Coagulation Factor IX (FIX)

Number of coagulation factor injections per bleed was determined. IU= international units, and kg= kilogram.

Time frame:
From Day 29 up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
Reported as:
Mean · IU/kg per year
Annualized Weight-Adjusted Consumption of Coagulation Factor VIII (FVIII) and Coagulation Factor IX (FIX)
IU/kg per yearOriginal Dose Regimen (SAS 1)AT-Based Dose Regimen (SAS 2)
FVIII63.66 ± 81.2952.13 ± 8.50
FIXs110.26 ± 93.74108.63 ± 138.42
SecondaryAnnualized Weight-Adjusted Consumption of Bypassing Agent (BPA) of Recombinant Factor VIIa (rFVIIa)

Number of BPA injections per bleed was determined.

Time frame:
From Day 29 up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
Reported as:
Mean · microgram/kg per year
Annualized Weight-Adjusted Consumption of Bypassing Agent (BPA) of Recombinant Factor VIIa (rFVIIa)
microgram/kg per yearOriginal Dose Regimen (SAS 1)AT-Based Dose Regimen (SAS 2)
Annualized Weight-Adjusted Consumption of Bypassing Agent (BPA) of Recombinant Factor VIIa (rFVIIa)1316.19 ± 2631.871431.84 ± 2369.29
SecondaryAnnualized Weight-Adjusted Consumption of Bypassing Agent (BPA) of Activated Prothrombin Complex Concentrate (aPCC)

Number of BPA injections per bleed was determined.

Time frame:
From Day 29 up to end of the study, maximum of up to 76 months
Reported as:
Mean · units/kg per year
Annualized Weight-Adjusted Consumption of Bypassing Agent (BPA) of Activated Prothrombin Complex Concentrate (aPCC)
units/kg per yearOriginal Dose Regimen (SAS 1)
Annualized Weight-Adjusted Consumption of Bypassing Agent (BPA) of Activated Prothrombin Complex Concentrate (aPCC)381.81 ± 409.82
SecondaryChange From Baseline in EuroQoL 5-Dimension 5-level Questionnaire (EQ-5D-5L) Index and Visual Analog Scale (VAS) Scores at Month 24

The EQ-5D-5L is a standardized and disease-generic instrument for use as a measure of quality of life (QoL) outcome. The EQ-5D-5L consists of 2 parts: EQ-5D descriptive system and EQ VAS. The EQ-5D descriptive system included questions for each of following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The VAS recorded participant's self-rated health on a vertical 20-centimeter. VAS scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). The EQ-5D-5L questionnaire scores range from 0-100, where 0= worst self-perceived health and 100= best self-perceived health. Positive change from baseline indicates an improvement in QoL. Baseline refers to the last non-missing value on or before the first significant treatment in TDR14767(ALN-AT3SC-001) or LTE14762 study.

Time frame:
Baseline and Month 24
Reported as:
Mean · units on a scale
Change From Baseline in EuroQoL 5-Dimension 5-level Questionnaire (EQ-5D-5L) Index and Visual Analog Scale (VAS) Scores at Month 24
units on a scaleOriginal Dose Regimen (SAS 1)AT-Based Dose Regimen (SAS 2)
Index score0.01 ± 0.140.09 ± 0.06
VAS score4.73 ± 18.3716.67 ± 7.64
SecondaryChange From Baseline in Hemophilia Quality of Life Questionnaire (Haem-A-QoL) Total Score and Physical Health Scores at Month 24

The Haem-A-QoL questionnaire is psychometrically tested QoL assessment instrument for participants with hemophilia and includes 46 items contributing to 10 QoL domains (physical health, feelings, view of yourself, sports and leisure, work and school, dealing with hemophilia, treatment, future, family planning, partnership and sexuality). Scoring for each item is based on a 5-point Likert scale (1= never, 2= rarely, 3= sometimes, 4= often, and 5= all the time), and the physical health and total transformed scores range from 0 to 100. Higher scores indicated greater impairment. Baseline refers to the last non-missing value on or before the first significant treatment in TDR14767(ALN-AT3SC-001) or LTE14762 study.

Time frame:
Baseline and Month 24
Reported as:
Mean · units on a scale
Change From Baseline in Hemophilia Quality of Life Questionnaire (Haem-A-QoL) Total Score and Physical Health Scores at Month 24
units on a scaleOriginal Dose Regimen (SAS 1)AT-Based Dose Regimen (SAS 2)
Total score-0.20 ± 0.470.02 ± 0.34
Physical health score-0.14 ± 0.58-0.53 ± 0.61
SecondaryAntithrombin Activity Level at the End of Treatment Regimen

The AT activity level was analyzed up to end of treatment regimen. The baseline under the original dose and regimen was the last non-missing assessment before the first significant dose.

Time frame:
From Day 29 up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
Reported as:
Mean · percentage
Antithrombin Activity Level at the End of Treatment Regimen
percentageOriginal Dose Regimen (SAS 1)AT-Based Dose Regimen (SAS 2)
Antithrombin Activity Level at the End of Treatment Regimen16.28 ± 4.5324.76 ± 7.36
SecondaryThrombin Generation at the End of Treatment Regimen

The TG data was analyzed by CoagScope and assay performed using calibrated automated thrombogram method. The baseline under the original dose and regimen was the last non-missing assessment before the first significant dose.

Time frame:
From Day 29 up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months)
Reported as:
Mean · nanomoles/liter
Thrombin Generation at the End of Treatment Regimen
nanomoles/literOriginal Dose Regimen (SAS 1)AT-Based Dose Regimen (SAS 2)
Thrombin Generation at the End of Treatment Regimen71.39 ± 24.6732.31 ± 20.05
SecondaryMaximum Observed Concentration (Cmax) of Fitusiran

Cmax was defined as maximum plasma concentration observed. The non-compartmental Pharmacokinetic (PK) analysis was performed.

Time frame:
Pre-dose and 0.5, 2, 4, 8 and 24 hours post-dose on Day 1, and Months 12 and 24
Reported as:
Mean · nanogram per milliliter (ng/mL)
Maximum Observed Concentration (Cmax) of Fitusiran
nanogram per milliliter (ng/mL)Fitusiran 50 mgFitusiran 80 mg
Day 186.8 ± 44.1168 ± 74.6
Month 1275.2 ± 50.3149 ± 53.2
Month 2462.5 ± 35.3155 ± 87.9
SecondaryTime to Reach the Maximum Concentration (Tmax) of Fitusiran

tmax was defined as time to reach Cmax. The non-compartmental PK analysis was performed.

Time frame:
Pre-dose and 0.5, 2, 4, 8 and 24 hours post-dose on Day 1, and Months 12 and 24
Reported as:
Median · hour
Time to Reach the Maximum Concentration (Tmax) of Fitusiran
hourFitusiran 50 mgFitusiran 80 mg
Day 13.97 (0.50 to 8.08)4.00 (2.00 to 8.07)
Month 124.02 (2.00 to 8.00)6.00 (2.02 to 8.03)
Month 244.00 (4.00 to 4.00)7.83 (4.05 to 8.00)
SecondaryArea Under the Concentration Versus Time Curve From Time 0 to the Real Time (AUClast) of Fitusiran

AUClast was defined as area under the concentration versus time curve from time 0 to the last measurable concentration. The non-compartmental PK analysis was performed.

Time frame:
Pre-dose and 0.5, 2, 4, 8 and 24 hours post-dose on Day 1, and Months 12 and 24
Reported as:
Mean · ng*hour/mL
Area Under the Concentration Versus Time Curve From Time 0 to the Real Time (AUClast) of Fitusiran
ng*hour/mLFitusiran 50 mgFitusiran 80 mg
Day 11110 ± 4862130 ± 769
Month 12961 ± 5512020 ± 708
Month 24935 ± 5502070 ± 917
SecondaryArea Under the Concentration Versus Time Curve Extrapolated to Infinity (AUCinf) of Fitusiran

AUCinf was defined as area under the concentration versus time curve extrapolated to infinity. The non-compartmental PK analysis was performed.

Time frame:
Pre-dose and 0.5, 2, 4, 8 and 24 hours post-dose on Day 1 and Month 12
Reported as:
Mean · ng*h/mL
Area Under the Concentration Versus Time Curve Extrapolated to Infinity (AUCinf) of Fitusiran
ng*h/mLFitusiran 50 mgFitusiran 80 mg
Day 11470 ± 4412230 ± 641
Month 12356 ± NA2860 ± NA
SecondaryTerminal Half-Life (t1/2z) of Fitusiran

t1/2z associated with the terminal slope (λz) determined according to the following equation: t1/2z = 0.693/λz; where, λz is the slope of the regression line of the terminal phase of the plasma concentration versus time curve, in semi-logarithmic scale. The non-compartmental PK analysis was performed.

Time frame:
Pre-dose and 0.5, 2, 4, 8 and 24 hours post-dose on Day 1 and Month 12
Reported as:
Mean · hour
Terminal Half-Life (t1/2z) of Fitusiran
hourFitusiran 50 mgFitusiran 80 mg
Day 15.19 ± 1.615.90 ± 3.83
Month 123.91 ± NA4.94 ± NA
SecondaryApparent Total Body Clearance (CL/F) of Fitusiran

CL/F was defined as apparent clearance of study drug from the body. The non-compartmental PK analysis was performed.

Time frame:
Pre-dose and 0.5, 2, 4, 8 and 24 hours post-dose on Day 1 and Month 12
Reported as:
Mean · liter per hour
Apparent Total Body Clearance (CL/F) of Fitusiran
liter per hourFitusiran 50 mgFitusiran 80 mg
Day 137.6 ± 13.638.8 ± 12.7
Month 12143 ± NA28.3 ± NA
SecondaryApparent Volume of Distribution at the Steady State After Single Extravascular Dose (Vss/F) of Fitusiran

Vss/F was defined as apparent volume of distribution of study drug at steady state concentration. The non-compartmental PK analysis was performed.

Time frame:
Pre-dose and 0.5, 2, 4, 8 and 24 hours post-dose on Day 1 and Month 12
Reported as:
Mean · liter
Apparent Volume of Distribution at the Steady State After Single Extravascular Dose (Vss/F) of Fitusiran
literFitusiran 50 mgFitusiran 80 mg
Day 1283 ± 155390 ± 348
Month 12834 ± NA204 ± NA
SecondaryRecovery of Fraction of the Dose Excreted in Urine (fe) in 0-24 Hours After Fitusiran Administration

fe was defined as the amount of fitusiran excreted in urine in 0-24 hour. The non-compartmental PK analysis was performed.

Time frame:
Postdose, 0 to 6 hours, 6 to 12 hours, 12 to 24 hours at Month 24
Reported as:
Mean · percentage of study drug
Recovery of Fraction of the Dose Excreted in Urine (fe) in 0-24 Hours After Fitusiran Administration
percentage of study drugFitusiran 50 mgFitusiran 80 mg
Recovery of Fraction of the Dose Excreted in Urine (fe) in 0-24 Hours After Fitusiran Administration10.7 ± 4.0812.6 ± 4.92

Adverse events

Collected over TEAEs data was collected from first dose of study drug (Day 1) up to end of the study (SAS 1: up to 76 months and SAS 2: up to 40 months).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Original Dose Regimen (SAS 1)1/34 (2.9%)13/34 (38.2%)33/34 (97.1%)
AT-Based Dose Regimen (SAS 2)0/18 (0%)1/18 (5.6%)13/18 (72.2%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventOriginal Dose Regimen (SAS 1)AT-Based Dose Regimen (SAS 2)
CholecystitisHepatobiliary disorders2/340/18
Hepatocellular CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/341/18
Atrial ThrombosisCardiac disorders1/340/18
Gastric Ulcer HaemorrhageGastrointestinal disorders1/340/18
GastritisGastrointestinal disorders1/340/18
Gastroduodenal UlcerGastrointestinal disorders1/340/18
Gastrointestinal HaemorrhageGastrointestinal disorders1/340/18
Gastrooesophageal Reflux DiseaseGastrointestinal disorders1/340/18
Haemorrhagic Erosive GastritisGastrointestinal disorders1/340/18
Peptic Ulcer HaemorrhageGastrointestinal disorders1/340/18
Most frequent other events
Showing 10 of 181
Most frequent other events
EventOriginal Dose Regimen (SAS 1)AT-Based Dose Regimen (SAS 2)
Alanine Aminotransferase IncreasedInvestigations10/340/18
HeadacheNervous system disorders9/341/18
ArthralgiaMusculoskeletal and connective tissue disorders8/341/18
Injection Site ErythemaGeneral disorders7/340/18
NasopharyngitisInfections and infestations7/341/18
DiarrhoeaGastrointestinal disorders6/340/18
Upper Respiratory Tract InfectionInfections and infestations6/341/18
Back PainMusculoskeletal and connective tissue disorders6/340/18
Transaminases IncreasedInvestigations5/341/18
Abdominal PainGastrointestinal disorders4/340/18

Baseline characteristics

Safety analysis set 1 included all participants who received at least a partial dose of study drug during the LTE14762 study under the original dose and regimen.

Age, Continuous
Age, Continuous(years)Original Dose Regimen (SAS 1)
Mean36.6 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)Original Dose Regimen (SAS 1)
Female0
Male34
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Original Dose Regimen (SAS 1)
Caucasian/White33
Asian/Oriental1
08

Study locations

12 sites
  • Clinical Trial Site
    Ann Arbor, Michigan 48109, United States
  • Clinical Trial Site
    Pittsburgh, Pennsylvania, United States
  • Clinical Trial Site
    Plovdiv, Bulgaria
  • Clinical Trial Site
    Sofia, Bulgaria
  • Clinical Trial Site
    Kirov, Russian Federation
  • Clinical Trial Site
    Moscow, Russian Federation
  • Clinical Trial Site
    Zurich, Switzerland
  • Clinical Trial Site
    Basingstoke, United Kingdom
  • Clinical Trial Site
    Glasgow, United Kingdom
  • Clinical Trial Site
    London, NW3 2QG, United Kingdom
  • Clinical Trial Site
    London, SW17 0QT, United Kingdom
  • Clinical Trial Site
    Truro, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2015 to primary completion in Mar 2023, 90 months.

Results were first posted in Jun 2024, 1 year 2 months after primary completion.

Of 20 phase 1/2 interventional studies under Hemophilia A, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 94. This study's 90 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2015
First posted
Sep 18, 2015
StartActual
Sep 18, 2015
Primary completionActual
Mar 21, 2023
CompletionActual
Mar 21, 2023
Results first posted
Jun 5, 2024
Last update
Jun 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02554773
Responsible party
Sponsor
First posted
Sep 18, 2015
Start date
Sep 18, 2015
Primary completion
Mar 21, 2023
Completion
Mar 21, 2023
Results posted
Jun 5, 2024
Last update
Jun 5, 2024

Study contacts

Clinical Sciences & Operations, MD
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fitusiran

Start the discussion